Suneva to Acquire Worldwide Rights to Refissa(R) -

Suneva to Acquire Worldwide Rights to Refissa(R)

June 4, 2012

Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with a .05% strength, emollient base and broad indication for fine facial lines, hyperpigmentation and tactile roughness. Financial terms were not disclosed. Nick Teti, Chairman and Chief Executive Officer of Suneva Medical commented, “This acquisition is very significant for Suneva on several levels. We are entering the prescription topical aesthetic market, a potential $100 million market opportunity, with a unique basket of products including Refissa®, which has the strength, formulation and a broad indication unlike any other tretinoin cream on the market today. This deal also allows us to offer aesthetic physicians a comprehensive anti-aging solution, which includes our ReGenicaTM skincare line, Refissa®, the gold standard topical treatment for fine lines and hyperpigmentation and our novel injectable filler, Artefill®.” Spear developed and received approval for a generic tretinoin cream as an ANDA to Renova .05% in 2005.

Facebook Comments

Title

Share on ReachMD

Get a Dose of PracticalDermatology in Your Inbox and Practice Smarter Medicine